Nano Biotherapeutics
Nano Biotherapeutics is dedicated to treating acute and chronic inflammation and tissue injury in the heart and lungs through albumin nanoparticle mediated drug delivery. Supported by NIH STTR, the company originated from research at the University of Illinois College of Medicine and focuses on nanotechnology and immunology to develop treatments for conditions such as ARDS and myocardial infarction.
Industries
Nano Biotherapeutics
Chicago, Illinois, United States, North America
Products
Albumin nanoparticle drug delivery platform
A drug delivery platform based on albumin-derived nanoparticles designed to deliver therapeutic agents to the lungs and heart for treatment of inflammatory and tissue-injury conditions.
Albumin nanoparticle drug delivery platform
A drug delivery platform based on albumin-derived nanoparticles designed to deliver therapeutic agents to the lungs and heart for treatment of inflammatory and tissue-injury conditions.
Services
Platform-based therapeutic R&D using albumin nanoparticles
Research and preclinical development of therapeutic candidates using an albumin nanoparticle delivery platform for targeting inflammatory and tissue-injury conditions in the lungs and heart.
Platform-based therapeutic R&D using albumin nanoparticles
Research and preclinical development of therapeutic candidates using an albumin nanoparticle delivery platform for targeting inflammatory and tissue-injury conditions in the lungs and heart.
Expertise Areas
- Nanoparticle drug delivery
- Pulmonary disease therapeutics
- Cardiovascular injury therapeutics
- Inflammation biology
Key Technologies
- Albumin-based nanoparticles
- Nanoparticle-mediated drug delivery systems
- Targeted pulmonary and cardiac delivery
- Preclinical in vivo disease models